Location History:
- Seuzach, CH (2005 - 2013)
- Winterthur, CH (2005 - 2018)
Company Filing History:
24 out of 31 
1 out of 29 
1 out of 1 Years Active: 2005-2018
Title: Martin F. Bachmann: An Innovator in Immunology
Introduction: Martin F. Bachmann, located in Seuzach, Switzerland, is an accomplished inventor with an impressive portfolio of 27 patents. His work primarily focuses on immunology and the development of innovative methods for enhancing immune responses through novel approaches involving virus-like particles (VLPs).
Latest Patents: One of Bachmann's latest patents involves the packaging of immunostimulatory substances into virus-like particles. This invention describes a method of preparation and use for loading VLPs with specific DNA oligonucleotides that contain non-methylated C and G sequences (CpGs). These CpG-VLPs have shown to be significantly more immunogenic compared to their CpG-free counterparts. The resulting immune response is characterized by enhanced B and T cell activity. This advancement could lead to effective vaccinations against a variety of health challenges, such as allergies, tumors, and chronic viral diseases.
Career Highlights: Throughout his career, Martin F. Bachmann has made significant contributions to the field of biotechnology. He has worked at notable companies, including Cytos Biotechnology AG and Novartis Pharma AG, where he has played a crucial role in driving forward cutting-edge research and innovative product development.
Collaborations: Bachmann has collaborated with other esteemed professionals in the field, including Patrik Maurer and Alain Tissot. These partnerships have fostered knowledge sharing and contributed to the success of his innovative projects.
Conclusion: Martin F. Bachmann exemplifies dedication and ingenuity in the realm of immunology. With his numerous patents and collaborative efforts, he continues to pave the way for groundbreaking advancements that hold the potential to transform treatments and preventative measures in healthcare. His work with virus-like particles demonstrates a leading-edge approach to enhancing immunogenicity and offers exciting possibilities for future vaccine development.